Cellebrite DI: Strong Q3, But Valuation And Technical Issues Could Weigh On The Stock (Rating Downgrade)

Cellebrite posted Q3 results that beat expectations with revenue of $126m (+18% y/y, $3m above consensus), EPS of $0.14 (flat y/y, $0.01 beat), subscription revenue up 21% and ARR of $440m (+19% y/y, +5% sequential); adjusted EBITDA rose 20% to $37.7m and margin expanded to 29.9% even as gross and operating margins compressed due to cloud infrastructure and federal ATO investments. Management narrowed 2025 revenue guidance to $470–475m (consensus $473m) and raised adjusted EBITDA to $124–127m, pointing to growth drivers including Guardian/Guardian Investigate, Pathfinder and the planned Corellium acquisition ($150–160m, expected close Q4 2025) to expand TAM and add to ARR. Despite solid execution, the analyst flags high valuation (PEG ~2.08, forward PE ~34x, P/S ~9x vs. sector medians), a bearish technical picture and concentration in government customers amid intense competition, and has lowered the rating to HOLD, warning the stock may underperform near term.

Analysis

Cellebrite's Q3 2025 results showed operational momentum with revenue of $126.0 million (+18% YoY, $3m above consensus) and EPS of $0.14 (flat YoY, $0.01 beat); subscription revenue rose 21% and subscription software represented ~89% of revenue while ARR reached $440 million (+19% YoY, +5% sequential). Adjusted EBITDA increased 20% to $37.7 million and margin expanded to 29.9%, even as gross profit of $106.5 million reflected a slight gross-margin decline to 84.9% driven by a 31.5% YoY rise in cost of revenue tied to cloud and federal ATO investments. Management narrowed 2025 revenue guidance to $470–475 million (consensus $473m) and raised adjusted EBITDA guidance to $124–127 million; growth initiatives include accelerating Guardian adoption (Guardian customers doubled YoY, ARR +100% for five consecutive quarters), a Q1 2026 Guardian Investigate launch, Pathfinder/Inseyets expansion, and the planned Corellium acquisition ($150–160m, expected close Q4 2025) which management says will add a couple of ARR percentage points. Valuation and technicals are key near-term restraints: PEG ~2.08 (vs sector 1.57), forward P/E ~34x and P/S ~9x materially exceed sector medians, consensus projects earnings growth of 21% in 2025 then 7.4% in 2026, the stock has fallen from roughly $20 to $16.81 with RSI below 50 and MACD momentum waning, and concentration in government customers (~90% historically) plus intense competition present execution risks; the analyst lowered the rating to HOLD.

Key Decisions for Investors

• Maintain or trim positions rather than add material new exposure given rich valuation (PEG ~2.08, forward P/E ~34x) and bearish technical signals
• Monitor catalysts closely: confirm Corellium close (expected Q4 2025), Guardian Investigate launch (target Q1 2026), ARR trajectory, Guardian customer additions and renewal rates before increasing allocation
• Consider hedging or defined downside protection (stop-loss or options) to guard against further near-term selling while integration and cloud investments proceed
• Reassess for accumulation only if valuation compresses toward sector medians or 2026 growth forecasts re-accelerate materially above current consensus